medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2017, Number 5

<< Back Next >>

Rev Mex Urol 2017; 77 (5)

Priapism: Comorbidities, treatment, complications, and sexual function

Carrillo-Córdova LD, Acevedo-García C, Rivera-Astorga H, Garduño-Arteaga LM

Language: Spanish
References: 23
Page: 383-388
PDF size: 277.73 Kb.


ABSTRACT

Background: Priapism is an uncommon alteration that mainly affects the corpora cavernosa, resulting in a persistently erect penis with or without sexual stimulation, lasting for 6 hours or more.
Objetive: To estimate the prevalence of comorbidities, treatment, complications, and results associated with patients with priapism.
Materials and Methods: A retrospective study employing case record information on patients diagnosed with priapism was conducted. Comorbidities, treatment, complications and results associated with the disease were evaluated. Diagnosis was clinical and confirmed through blood gasometry of the corpora cavernosa. Treatment followed the American Urological Association and the European Association of Urology guidelines. The decision of which type of corporo-spongiosal shunt to use was based on the treating surgeon’s criterion. Early complications were described according to the Clavien-Dindo classification. Erectile function recovery was evaluated through a telephone interview.
Results: Fourteen patients were enrolled in the study (13 with low-flow priapism confirmed through gasometry [pH ‹ 7.23] and 1 with high-flow priapism). The most frequently associated comorbidity was mental illness, which included substance abuse. Cavernositis was the most common acute complication and erectile dysfunction was the most common chronic complication. Of the patients with ischemic priapism, only 1 was cured with conservative treatment (NSAID) and the remaining 12 with intracavernous irrigation.
Conclusion: Psychiatric illnesses were highly prevalent in the patients with priapism and the erectile dysfunction rate was higher than that reported in other case series. Our study results can improve knowledge of priapism in the Mexican population.


REFERENCES

  1. Montague DK, Jarow J, Broderick GA, et al. American Urological Association Guideline On The Management Of Priapism. J Urol. 2003;170(4):1318-1324.

  2. Muneer A, Ralph D. Guideline of Guidelines Priapism. BJU Int. 2016;119(2);204-8.

  3. Salonia A, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Vardi Y, Wespes E, Hatzimouratidis K. European Association of Urology guidelines on priapism. European Association of Urology. Eur Urol;2014;65(2):480-9.

  4. Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology 2001;57:970-2.

  5. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334:873-7.

  6. Tarry WF, Duckett JW, Synder HM. Urological complications of sickle cell disease in a pediatric population. J Urol. 1987;138:592-4-7

  7. Ewalt D, Cavender J, Buchanan G, Rogers Z. Leuprolide therapy prevents recurrent priapism in teenage boys with SCA. Paediatrics. 1996; 88:643.

  8. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21:518-22.

  9. Burnett AL. Pathophysiology of priapism: dysregulatory erection physiology thesis. 2003;170:26-34.

  10. Dindo D, Demartines N, Clavien PA, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213.

  11. Gottsch HP, Berger RE, Yang CC. Priapism: comorbid factors and treatment outcomes in a contemporary series. Adv Urol. 2012;2012:672624. doi: 10.1155/2012/672624. Epub 2012 Jul 3.

  12. Fu E, Kovach JG, Dubin WR. priapism associated with antipsychotic medication use: case report. J Clin Psychopharmacol 2017;37(4):477-8R.

  13. Fiorelli L, Manfrey SJ, Belkoff LH, Finkelstein LH. Priapism associated with intranasal cocaine abuse. J Urol. 1990;143(3):584-585.

  14. Ahmed M, Augustine B, Matthew M, Awaisu M, Sudi A, Hamza KB, et al. Prognostic factors and outcome of management of ischemic priapism in Zaria, Nigeria. Niger J Surg. 2017;23(1):15-9.

  15. Munarriz R, Hwang J, Goldstein I, Traish AM, Kim NN. Cocaine and ephedrine-induced priapism: case reports and investigation of potential adrenergic mechanisms. Urology-2003;62(1):187-192.

  16. Kulmala R, Lehtonen T, Nieminen P, Tammela T. Aetiology of priapism in 207 patients. Eur Urol. 1995;28(3):241-245.

  17. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism associated with antipsychotics: role of α1 adrenoceptor affinity. J Clin Psychopharmacol. 2010;30(1);68-71.

  18. Bar KJ, Boettger MK, Schulz S, et al. Reduced cardio-respiratory coupling in acute alcohol withdrawal. Drug Alcohol Depend. 2008;98(3):210-–217.

  19. Vongpatanasin W, Mansour Y, Chavoshan B, Arbique D. Cocaine stimulates the human cardiovascular system via a central mechanism of action. Circulation.1999;100(5):497-502.

  20. Henry BL, Minassian A, Paulus MP, Geyer MG, Perry W. Heart rate variability in bipolar mania and schizophrenia. J Psychiatric Res. 2010;44(3):168-176.

  21. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104(17):2024-2028.

  22. Hinman F. Priapism: report of cases and a clinical study of the literature with reference to its pathogenesis and surgical treatment. Ann Surg. 1914;60:689-716.

  23. Torres-Ochoa DE, Delgado-Guerrero F, Torres-Aguilar J, Lugo-García JA. Etiología y manejo de priapismo en el Hospital Juárez de México. Bol Coleg Mex Urol 2016;31(3):87-89.




2020     |     www.medigraphic.com